Introduction
The development of colorectal cancer is a multistep process, often referred to as the adenoma-carcinoma sequence (Vogelstein et al., 1988) . In general, it takes 10-15 years to progress from normal colorectal epithelium, via the stage of an adenoma, to colorectal cancer. This time span provides a window of opportunity for chemoprevention, especially in high-risk patients with a history of an adenoma or cancer. In addition, chemoprevention is considered important for patients with familial adenomatous polyposis or Lynch syndrome, disorders that strongly predispose to the development of colorectal cancer (Arber and Levin, 2008) . The urgent need for more effective chemoprevention warrants research on the biological background of colorectal adenoma formation to reveal possible targets.
The development of the microarray technique has made it possible to perform whole genome expression profiling of different disease states (Lockhart et al., 1996) . Despite the high incidence of colorectal adenomas, surprisingly few microarray studies have been performed comparing normal mucosa and adenomas (Lin et al., 2002; Kita et al., 2006; Sabates-Bellver et al., 2007; Galamb et al., 2008) . Performing analysis on premalignant phenotypes is of special interest as these lesions represent a relatively homogeneous condition, providing information about the initial changes during colorectal carcinogenesis and about putative targets for chemoprevention. Integrating publicly available data of small studies profiling normal and adenoma tissue into one analysis will increase the power to detect biological relevant signals specific for adenoma formation.
In the conventional method of analyzing microarray data, only the top few individual genes that are highly differentially expressed between two phenotypes are reviewed (Lockhart et al., 1996) . Although such individual genes may prove to be relevant for adenoma formation, it is increasingly doubted whether large fold changes in individual genes will have more biological relevance than smaller but coordinated fold changes in a set of genes encoding proteins lying along a single pathway (Bild et al., 2006) . As in biological processes genes often cooperate in the so-called biological pathways, analyzing microarray data at the level of pathways might provide us with more insight into biological mechanisms associated with the development of adenomas (Vogelstein and Kinzler, 2004) . In addition, integrating genes into functional sets enables us to consider all genomic information available from a microarray platform rather than focusing on individual genes passing a certain significance threshold (Subramanian et al., 2005; Bild et al., 2006; Crijns et al., 2009) .
Therefore, the aim of this study was: (1) to analyze differences in pathway enrichment between normal mucosa and adenomas in a combined set of publicly available microarray expression data; (2) to validate these results in a newly generated data set of human normal colonic epithelium and adenoma samples; and (3) to examine the functional relevance of targeting enriched pathways in adenoma cell lines.
Results
Data acquisition, quality control and standardization Table 1 shows the data sets obtained from the Gene Expression Omnibus (GEO) that were initially included in the study. Quality control was performed with principal component analysis (PCA). Figure 1 shows that the correlations (factor loadings) between the arrays and the first principal component (PC) named PCqc were highly similar. However, the study with GEO series (GSE) accession number GSE9254 contains samples with distinctly lower correlations with the PCqc, indicating that this data set is of lower quality. We therefore excluded samples belonging to this data set from further analysis.
We reanalyzed the data with PCA after all arrays from GSE9254 had been excluded from the combined data set. The PCqc explained 94.8% of the total variance in expression. All arrays now showed highly similar correlation (factor loadings) with the PCqc (mean factor loading 0.97, range 0.93-0.99). Subsequently, we standardized our data by subtracting the variance explained by the PCqc as this represents probe-specific variation that does not contribute to differences between arrays.
Minimizing multiple study expression artifacts Performing PCA on the standardized data revealed two dominant principal components, which explained a large amount of the total variance in expression in our standardized data set. PC1 and PC2 explained 26.8 and 14.5%, respectively, of the total variance in expression ( Figure 2c ). We expected that the variance in expression explained by the first two PCs would be driven primarily by tissue type (normal colorectal mucosa vs adenoma) and multiple study selection. Figures 2a and b show a scatter plot of the correlations (factor loadings) of individual arrays with PC1 and PC2. In Figure 2a samples are labeled according to their tissue type and in Figure 2b according to study origin (GSE accession number). Figure 2a shows that there is a clear separation in factor loadings with PC1 between normal colorectal mucosa and adenoma, but no such clear separation in factor loadings with PC2. This indicates that PC1 captures variance in expression that can be attributed to differences in tissue type. Figure 2b illustrates that samples belonging to GSE4183 have highly similar factor loadings with PC2. As GSE4183 contains both normal colorectal mucosa and adenoma samples, the variance explained by PC2 cannot be attributed to tissue differences. Therefore, we concluded that PC2 captures Figure 1 Factor loadings of each individual array with the PCqc (from principal component analysis). Factor loadings are highly similar, indicating comparable array quality. Arrays from GSE9254 were excluded from the final analysis because of their lower factor loadings with the PCqc. 
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Abbreviation: GSE, gene expression omnibus series. Note: GSE accession numbers can be used to query the data set in GEO (http://www.ncbi.nlm.nih.gov/geo/).
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Cluster array
Hierarchical clustering analysis separated normal colorectal mucosa and adenoma samples into two distinct groups. This illustrates that the variation in expression is mainly the consequence of differences in tissue types and not of experimental artifacts (Supplementary Figure 1) .
Differential individual gene expression in adenomas
We found upregulation of several genes in adenomas that are known to be involved in colorectal carcinogenesis such as cyclin D1 (Arber et al., 1996) , MMP7 (Guillen-Ahlers et al., 2008) and CD44 (Imazeki et al., 1996) , and also of many more genes with an unknown biological relevance. A heat map of the top-100 individual genes either up-or downregulated in adenomas vs normal mucosa is shown in Figure 3 .
Pathway enrichment in adenomas
Gene set enrichment analysis (GSEA) using pathway definitions from Kyoto Encyclopedia of Genes and Genomes (KEGG) database revealed 10 significant gene sets specific to adenomas at a nominal P-value o0.05 and false discovery rate (FDR) o0.30. By using the KEGG database as an input for GSEA, several wellknown causal pathways (cell cycle, Wnt signaling), resulting pathways (DNA base metabolism, transcription) and compensatory pathways (p53 pathway) involved in carcinogenesis specifically distinguished adenomas from normal mucosa. In addition, the gene set for folate metabolism was upregulated in adenomas (Table 2a) . GSEA using pathway definitions from Gene Map Annotator and Pathway Profiler (GenMAPP) revealed 11 gene sets significantly enriched at a nominal P-value o0.05 and FDR o0.30 (Table 2b ). GSEA using pathway definitions from Biocarta revealed 15 gene sets significantly upregulated in adenomas at a nominal P-value o0.05 and FDR o0.30. The retinoblastoma (Rb) pathway showed the highest NES and P-values (Table 2c) .
Using the KEGG, GenMAPP and Biocarta databases, the pathways identified to distinguish adenomas from normal mucosa were often comparable, despite the differences in definitions of gene sets. These three well accepted and widely used databases not only differ in their pathway definitions, but also offer different analyzable gene sets. For example, the newly discovered Rb, Src and PTC1 (Hedgehog) pathways enriched in adenomas are not present, as such, in the KEGG and GenMAPP databases, whereas they were highly significantly upregulated in adenomas according to the Biocarta database.
Enrichment plots for Rb pathway, cell cycle and p53 pathway are shown in Figure 4 .
External validation of deregulation of the Rb and Src pathway by qRT-PCR
To validate results obtained by our pathway analysis in a newly generated data set, we performed quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) for genes from two of the enriched pathways in the Biocarta database, which are defined by relatively small gene sets. We chose the Rb and Src pathways, because these routes were highly significantly differentially expressed between normal colonic epithelium and adenomas, whereas at the same time an inhibitor was available to test the functional relevance of these pathways. We compared the expression of six different genes from the Rb pathway and three different genes from the Src pathway with qRT-PCR on mRNA isolated from an independent set of adenoma tissue (n ¼ 16) and normal colonic epithelium (n ¼ 8). For all six Rb pathway genes (Rb1, CDK2, CDC2, p53, CDK4, CCND1) and all three Src pathway genes (Src, CDC2, CCNB1), mRNA expression was higher in adenoma tissue, in concordance with the microarray results. Notably, for most genes, the rank in the gene list corresponded with the relative change in expression as reflected by the DDCt value (Tables 3a and b). As a control for the reliability of the qRT-PCR experiments, the mRNA expression of ABCG2 was investigated since 
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Functional targeting of the Rb and Src pathways in colon adenoma cell lines
To examine the functional relevance of performing pathway analysis as described above, we used functional inhibitors for two different pathways. The broad spectrum cyclin-dependent kinase (CDK) inhibitor roscovitine was used to inhibit Rb pathway activation. Treatment of both adenoma cell lines VACO-235 and VACO-330 with roscovitine led to a dose-dependent induction of apoptosis (Figures 5a-c) (growth reduction is shown by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in Supplementary Figure 2 ). Western blot analysis indeed revealed a clear dosedependent reduction in expression of both total and phosphorylated Rb and cyclin D1. As expected, CDK2 levels were unchanged as roscovitine inhibits CDK2 activity and not protein expression (Whittaker et al., 2004) . P53, and subsequently p21, were strongly upregulated by roscovitine. In the highest concentration, p21 levels were reduced, likely due to caspase-dependent Pathway finding in colorectal adenomas DM Heijink et al cleavage ( Figure 5d ). Normal fibroblasts and lung epithelial cells were not sensitive to roscovitine, yielding a therapeutic window for targeting this pathway (Figure 5e ). To examine the functional relevance of Rb pathway inhibition using a more specific inhibitor, VACO cells were also treated with the novel highly specific CDK4/6 inhibitor PD-0332991. After 5 days of treatment, significant growth reduction was observed along with a decrease in the level of phospho-Rb (Supplementary Figure 3) . The tyrosine kinase inhibitor dasatinib was used to inhibit Src pathway activation. Treatment of VACO-235 and VACO-330 cells with relatively low concentrations of dasatinib (p100 nM) did not result in apoptosis (data not shown), but in dose-dependent growth inhibition (Figure 6a ). Western blot results showed a dose-dependent reduction in levels of phospho-Src in the concentration range necessary for growth inhibition (Figure 6b ).
Discussion
Until now, integrated analysis of available microarray data from multiple studies is not a common approach. However, such an approach is very interesting as combining expression data has the important advantage of having more power to detect biological relevant signals by increasing the available number of samples to be studied. To our knowledge, we have analyzed the largest set of microarray expression data from normal colorectal mucosa and adenoma samples to generate hypotheses on which biological pathways are implicated in early colorectal carcinogenesis. Moreover, we showed how to use principal component analysis to screen for quality of microarray hybridization and how to minimize expression differences caused by multiple study selection. Finally, we validated expression of Rb and Src pathway components that were enriched in adenomas with qRT-PCR, and blocked the functionality of these pathways in adenoma cell lines as a proof-of-concept for our pathway analysis approach.
We identified individual significantly up-or downregulated genes in adenomas, including several genes known to be involved in colon carcinogenesis. However, integrating all genomic information in pathway analysis yielded even more interesting biologically relevant information. To date, such analyses have not been performed on colorectal adenomas. A number of identified pathways are already known in the literature to play a significant role in colon carcinogenesis, indicating the validity of our approach. However, we identified in addition interesting new pathways that have received little attention in past research on adenomas of the colorectum. These pathways will provide potentially new starting points for research on chemoprevention of colorectal cancer.
The pathways that were specifically enriched in adenomas in our analysis are known to be activated in colorectal carcinogenesis (causal, resulting or compensatory) such as the Wnt pathway (Midgley and Kerr, 1999) , cell cycle routes (Hao et al., 1998) , DNA base metabolism, transcription, ATM (Kwong et al., 2008; Paulson et al., 2008) , ARF, p27 (Payne et al., 2008) and p53 (Einspahr et al., 2006) signaling routes. In addition, we found novel pathways unique to adenomas, among which are the Rb pathway, the Src pathway, folate biosynthesis and the PTC1 pathway. Moreover, we revealed potentially new interesting pathways, of which the biological relevance for colon adenomas remains to be elucidated. Although the importance of these routes is likely to be the case in colon carcinomas, there is not enough evidence to speculate about implications and targeting of these routes in adenomas (Table 2 , for example, the Skp2, the p27 and the Ets pathway) (Timmerbeul et al., 2006; Wai et al., 2006; Fujita et al., 2008) .
We focused on two significantly enriched pathways in adenomas: the Rb pathway and the Src pathway. Rb is frequently inactivated or mutated in a wide variety Pathway finding in colorectal adenomas DM Heijink et al of tumors, thereby losing tumor suppressor function. In colon cancer paradoxically, the Rb protein is often overexpressed, which has been related to antiapoptotic responses, and could be a critical step in colon carcinogenesis (Arhel et al., 2003; Du and Searle, 2009 ). In adenomas, several components of the Rb route show aberrant expression at protein level (Bartkova et al., 2001; Zhao et al., 2006) . Src family kinases are involved in many tumorigenic events, including proliferation, survival, angiogenesis, adhesion, invasion and metastasis (Yeatman, 2004) . Increased expression of Src was seen in colonic adenomas (Cartwright et al., 1990) . Relative differences in mRNA expression of Rb and Src pathway players between adenomas and normal mucosa were highly similar when comparing the microarray data and RT-PCR results. CDK inhibitors are effective agents to target the Rb pathway (Senderowicz, 2003) . CDKs regulate progression of the cell cycle (mainly CDK2 and CDK4/6) and regulate transcription (mainly CDK7 and CDK9) (Wesierska-Gadek et al., 2011). The cell cycle regulating CDKs are part of the Rb pathway as they function-in complexes with cyclins-to stepwise phosphorylate Rb, resulting in the activation of E2F-mediated transcription and cell cycle progression (Giacinti and Giordano, 2006) . As with all second-generation CDK inhibitors, the CDK inhibitor roscovitine shows preferable activity against one CDK (the Rb pathway component CDK2), but it also inhibits other CDKs (especially CDK7/9) (Knudsen and Wang, 2010) . We found that roscovitine induced changes in the expression of proteins involved in the Rb pathway. Several changes are likely to be the result of CDK2 inhibition, including the loss of phospho-Rb and the upregulation of p53 (Arima et al., 2008) . However, other observed changes in the expression of Rb pathway proteins may be independent of CDK2 inhibition, but the result from CDK7/9 inhibition, such as the loss of cyclin D1 (Aldoss et al., 2009 ). In addition, CDK7/9 inhibition can contribute to apoptosis induction by roscovitine and related compounds . The CDK2/7/9 inhibitor SNS-032 was shown to be effective for chemoprevention of intestinal tumorigenesis in Ink4a/Arf-null Apc Min mice. The adenoma burden was reduced to 25% by lowering of the mitotic index and the induction of apoptosis (Boquoi et al., 2009) . We additionally tested PD-0332991, a highly specific novel small-molecule inhibitor of CDK4/6, the other CDKs involved in the Rb pathway. The antitumor effect of PD-0332991 is totally dependent on the presence of Rb, as this agent showed no activity against Rb-negative cells and RNAi depletion of Rb resulted in resistance in previously sensitive cell lines (Fry et al., 2004; Michaud et al., 2010) . Treatment of VACO adenoma cells with PD-0332991 resulted in growth reduction together with a reduction in phospho-Rb levels. Importantly, a recent study showed the functional importance of targeting the Rb pathway with this drug for CRC chemoprevention in vivo. In the Apc Min mouse model, treatment with PD-0332991 for 5 days resulted in a strong reduction of proliferation in intestinal adenomas (Cole et al., 2010) . The fact that CDK4/6 complexes and phospho-Rb levels are upregulated following Apc loss (in nearly all cases the first hit in colorectal carcinogenesis) highlights that activation of the Rb pathway is truly an early event during colorectal carcinogenesis, which makes it sensible to target this route for chemoprevention (Cole et al., 2010) . Whether Rb pathway inhibition by secondgeneration broad spectrum CDK inhibitors such as roscovitine or more selective inhibitors such as PD-0332991 are more suitable for colorectal chemoprevention is an interesting subject for future research. The simultaneous inhibition of cell cycle, activation of p53 and induction of apoptosis by roscovitine might be of advantage as it offers the possibility to hit adenoma cells via multiple ways. On the other hand, more selective compounds may exert less side effects, which is an important aspect of treatment in a chemopreventive setting. Src activation is blocked by the tyrosine kinase inhibitor dasatinib, which dually inhibits Src family kinases and Bcr-Abl, with the latter not being present in adenoma cells. Dasatinib is well tolerated and the drug has entered the clinic for patients with leukemia (Kantarjian et al., 2007) . Dasatinib has shown activity against colon cancer cells in preclinical models (Serrels et al., 2006; Kopetz et al., 2009) . The potential of dasatinib in adenomas has not been investigated yet. We show a growth reduction in colon adenoma cells at relatively low concentrations of dasatinib, indicating that the observed effects are Src specific (Li et al., 2010) . Our experiments are a proof-of-concept, showing that pathway analysis results in the identification of pathways related to carcinogenesis, which can finally lead to effective targeting of those pathways.
In conclusion, we have shown a bioinformatical and functional approach leading to potentially new therapeutic options for chemoprevention of colorectal cancer. 
Materials and methods
Data acquisition
We obtained microarray expression data from normal colorectal mucosa and adenomas from GEO (Edgar et al., 2002) . Data sets were included if they met all the following criteria:
(1) samples were hybridized to HG-U133 plus 2.0 (Affymetrix, Santa Clara, CA, USA), one of the most widely applied platforms providing a comprehensive coverage of the human genome. This array analyzes the expression level of over 47 000 transcripts and variants, including 38 500 well-characterized human genes; (2) raw data were available as an Affymetrix intensity file (CEL file) enabling us to pre-process the data in a uniform manner; and (3) normal mucosa samples were derived from healthy controls. Normal appearing mucosa from patients with an adenoma, cancer or inflammatory bowel disease was excluded as these entities can be accompanied by altered cellular properties of normal appearing epithelium (Koornstra et al., 2004) . Pre-processing and aggregation of CEL files was performed with Affymetrix Expression Console software. Expression summary was carried out using the robust multi-array average (RMA) algorithm. For final inclusion, the data sets had to pass our quality control as described in the following section.
Quality control and standardization Quality control was performed using PCA on the sample correlation matrix. The PCA method condenses a multidimensional data set into a set of lower dimensions, to reveal the simplified linear structure of the data that often underlies them (Rencher, 1998) . PCs are able to summarize expression information and are constructed in such a way that PC1 explains the largest amount of variance in expression and each subsequent PC explains the largest amount of the remaining variance in expression while remaining uncorrelated with previous PCs. The most significant PC for a gene expression data matrix is frequently a constant pattern, which dominates the data (Sherlock, 2001 ). This pattern can be regarded as probe-specific variance, independent of biological samples hybridized to the array. The first PC can be used as a quality control and is named here PCqc (Alter et al., 2000; Sherlock, 2001) . PCqc explaining the largest part of the variation could be considered as variation that the arrays have in common (Alter et al., 2000; Crijns et al., 2006) . We calculated correlations with PCqc (factor loadings) for each individual array. Factor loadings of PCqc can be seen as a quality index, as arrays of lesser quality would have lower or distinctly different correlations than arrays of good quality. By subtracting this common variation from the expression data, all the gene-specific variation that does not contribute to differences between arrays was eliminated (that is, the expression data was standardized by subtracting the first factor).
Minimizing multiple study expression artifacts
In our analysis, we expected to find an expression effect owing to the fact that samples were collected from multiple research groups, introducing systematic variation between the different data sets. By applying PCA on the standardized expression data, we aimed to identify the PC that could explain this systematic variation between the different data sets. For subsequent analysis, the variance explained by this PC was subtracted from all data to minimize this systematic variation between the data sets (Alter et al., 2000; Nielsen et al., 2002) .
Cluster analysis
Cluster analysis of samples was performed on the standardized and normalized data with average linkage hierarchical Pathway finding in colorectal adenomas DM Heijink et al clustering according to the Euclidean distance measure (square root of the sum of the squared differences in each dimension) by using the Cluster 3.0 software (de Hoon et al., 2004) .
Gene set enrichment analysis GSEA was performed with GSEA 2.0 (Broad Institute, Cambridge, MA, USA) (Mootha et al., 2003; Subramanian et al., 2005) . This method ranks genes according to their relative difference in expression (Student's t-statistic) between two phenotypes (normal colorectal mucosa vs adenomas). GSEA compares this list of ranked genes against a large collection of pathway data (gene sets) to determine if there is enrichment of one of these functional groupings. The list of ranked genes is processed from top to bottom. Whenever a gene belonging to the gene set of interest is found, a running enrichment score is increased by a certain amount according to the rank, otherwise the enrichment score is decreased. The enrichment statistic is the maximum deviation of the running enrichment score from zero. GSEA then reiteratively randomizes the sample labels a 1000 times and retests for enrichment across the random classes. The gene sets that significantly outperform iterative random-class permutations are considered significant. A significance threshold was set at a nominal P-value of 0.05 and an FDR of 0.30. FDR is the estimated probability that a gene set with a given enrichment statistic represents a false-positive finding. A gene set with an FDR o0.30 indicates that the result is likely to be valid 7 out of 10 times. These gene sets are considered most likely to generate interesting hypotheses and drive further research (Subramanian et al., 2005) . In our analysis, we assembled gene sets from well accepted and widely used curated pathway databases. A total of 169 functional gene sets as reported in the KEGG, 109 from the GenMAPP, and 187 as reported in the Biocarta database (http://www.biocarta.com/) were analyzed (Dahlquist et al., 2002; Kanehisa et al., 2006) .
Patient material
To validate our results generated on the integrated publicly available data, we obtained adenoma tissue from both low-grade dysplastic and high-grade dysplastic adenomas (n ¼ 16) and normal colonic epithelium (n ¼ 8) from individuals undergoing colonoscopy at the University Medical Center Groningen. Normal mucosa was obtained from individuals without a history of colorectal adenomas or cancer in which no aberrations were found at colonoscopy. The study protocol was approved by the medical ethical review committee of the University Medical Center Groningen. All patients gave written informed consent. Histological classification of adenomas was carried out on hematoxylin-eosin-stained slides by a pathologist. Samples were frozen in Tissue Teck and stored at À80 1C until analysis.
Real-time qRT-PCR RNA was isolated from patient material by guanidinium thiocyanate-phenol-chloroform extraction (Chomczynski and Sacchi, 1987) after purification of the tissue by using a MicroDismembrator U (B. Braun Biotech International, Melsungen, Germany). After DNAse treatment (RNAse-free DNAse, Amgen, Thousand Oaks, CA, USA), 1 mg of total RNA was reverse-transcribed using random primers (Invitrogen, Breda, the Netherlands). Ten nanogram of cDNA was subjected to real-time quantitative PCR on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Milan, Italy) using Taqman Universal PCR Mastermix and Assays-on-Demand (Applied Biosystems) specific for Rb pathway genes, Src pathway genes and ABCG2 following the manufacturer's instructions to detect corresponding mRNAs. The following assays were used: Rb1 (Hs01078060_m1), CDK2 (Hs00608082_m1), CDC2 (Hs00364293_m1), TP53 (Hs00153349), CDK4 (Hs00364847_ m1), cyclin D1 (Hs00277039_m1), cyclin B1 (Hs00259126_m1), Src (Hs00178494_m1) and ABCG2 (Hs00184979_m1). 18S rRNA was used as the reference gene for sample normalization and was amplified in separate wells within the same plate (Hs99999901_s1) (Galamb et al., 2008) . All determinations were performed in triplicate. For data analysis, the SDS 2.3 software was used. Gene expression results were calculated using the DCt method. Student's t-test was performed to compare the expression between normal and adenoma tissues.
Cell lines, drug treatment and quantification of apoptosis Two human colon adenoma cell lines, VACO-235 and VACO-330 (a kind gift from JK Wilson, MD, Ireland Cancer Center, Cleveland, OH, USA), derived, respectively, from a villous and tubular adenoma, were used. VACO cells were cultured on rat tail collagen-coated plates as described previously (Jalving et al., 2006) . Human bronchial epithelial cell line 16HBE and human lung fibroblasts IMR90 served to detect possible toxicity in normal cells. Cells were treated with increasing concentrations (0-100 mM) of the CDK inhibitor roscovitine (LC Laboratories, Woburn, MA, USA) for 24 h, with increasing concentrations (0-10 mM) of the specific CDK4/6 inhibitor PD-0332991 (a generous gift from Pfizer, Groton, CT, USA) for 5 days and with increasing concentrations (0-1000 nM) of the tyrosine kinase inhibitor dasatinib (LC Laboratories) for 48 h. Cell growth was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Apoptosis was quantified using M30 immunoreactivity (primary antibody: Cell Signaling Technology, Leusden, the Netherlands) on cytospins (adenoma cells) or by staining nuclear chromatin with acridine orange (10 mg/ml) and identifying appearance of apoptotic bodies and/or chromatin condensation by fluorescence microscopy (normal cells).
Western blot analysis
Preparation of protein lysates and western blotting was carried out as described previously (van Geelen et al., 2003) . The following primary antibodies were used: rabbit-anti-PARP (Boehringer, Mannheim, Germany), mouse-anti-phospho Rb (sc-102), rabbit-anti-cyclin D1 (sc-718), goat-anti-CDK2 (sc-F1404), mouse-anti-p53 (sc-126) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse-anti-p21 (Merck, Darmstadt, Germany), rabbit-anti-cleaved caspase-3 (no. 9661), rabbit-anti-Src (no. 2109) and rabbit-anti-phospho Src family (Tyr416) (no. 2101) (all from Cell Signaling Technology, Beverly, MA, USA). b-Actin (ICN Biomedicals, Zoetermeer, the Netherlands) expression levels served as loading control.
